抄録
This review briefly explains concept, methodology, and historical background of passive targeting of drug. Historically, it was believed that active targeting using monoclonal antibodies was a more selective and efficient targeting methodology than passive targeting. In contrast, all the approved targeting systems for anticancer drugs are of passive targeting. Authors emphasize significance of passive targeting, and point out that the passive targeting aspect is also important and must be carefully considered for potent active targeting system design because passive pharmacokinetic processes are included to a substantial degree in active targeting systems.
